The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MIST | +28.67% | -68.06% | -20.41% | -88% |
| S&P | +18.13% | +110.72% | +16.08% | +140% |
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | -7.7% |
| Market Cap | $103.72M | 47.5% |
| Market Cap / Employee | $3.14M | 0.0% |
| Employees | 33 | -29.8% |
| Net Income | -$12.97M | -38.5% |
| EBITDA | -$12.59M | -29.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $42.50M | 220.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $55.88M | 6.1% |
| Short Term Debt | $0.52M | -9.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -81.27% | -29.3% |
| Return On Invested Capital | -61.49% | -2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.06M | -119.4% |
| Operating Free Cash Flow | -$13.05M | -119.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.53 | 5.24 | 3.25 | -16.94 | -1062.10% |
| Price to Sales | 55.92 | - | |||
| Price to Tangible Book Value | 2.53 | 5.24 | 3.25 | -16.94 | -1062.14% |
| Enterprise Value to EBITDA | -8.10 | -9.37 | -2.56 | -11.26 | 90.52% |
| Return on Equity | -162.9% | -277.6% | -307.3% | -780.3% | 483.38% |
| Total Debt | $54.02M | $54.80M | $55.59M | $56.39M | 5.90% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
